Federated Hermes Inc. Boosts Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Federated Hermes Inc. grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 222.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 174,390 shares of the biopharmaceutical company's stock after purchasing an additional 120,249 shares during the quarter. Federated Hermes Inc. owned 0.15% of Catalyst Pharmaceuticals worth $3,640,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Farther Finance Advisors LLC grew its stake in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $65,000. KBC Group NV raised its position in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $134,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX traded up $0.33 during midday trading on Friday, reaching $22.52. 720,850 shares of the stock were exchanged, compared to its average volume of 1,139,890. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 3.31 and a beta of 0.79. The business's 50-day moving average price is $22.60 and its 200 day moving average price is $22.07.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CPRX has been the topic of a number of recent research reports. Robert W. Baird upped their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.